VIP Polyclonal antibody

VIP Polyclonal Antibody for IF, IHC, ELISA

Host / Isotype

Rabbit / IgG


human, mouse, rat





Cat no : 16233-1-AP


PHM27, vasoactive intestinal peptide, VIP, VIP peptides

Tested Applications

Positive IHC detected inhuman colon tissue, human small intestine tissue, mouse brain tissue, rat small intestine tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inCOLO 320 cells, mouse colon tissue

Recommended dilution

Immunohistochemistry (IHC)IHC : 1:20-1:200
Immunofluorescence (IF)IF : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

16233-1-AP targets VIP in IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivitymouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen VIP fusion protein Ag8933
Full Name vasoactive intestinal peptide
Calculated molecular weight 169 aa, 19 kDa
GenBank accession numberBC009794
Gene symbol VIP
Gene ID (NCBI) 7432
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Vasoactive intestinal peptide (VIP), a short peptide containing 28 amino acids belonging to the secretin-glucagon family, is initially isolated from the gastrointestinal tract as a potent vasodilator peptide. VIP was initially identified in normal nervous tissue and neurons and was subsequently recognized as a neurotransmitter widely distributed in various tissues. The wide distribution of VIP determines its involvement in a range of biological activities, such as gut motility, hormonal regulation, circadian rhythms, immune responses, and carcinogenesis. The general physiologic effects of VIP include vasodilation, anti-inflammatory actions, cell proliferation, hormonal secretion, regulation of gastric motility, and smooth muscle relaxation; therefore, VIP has emerged as a promising drug candidate for the treatment of several diseases.


Product Specific Protocols
IHC protocol for VIP antibody 16233-1-APDownload protocol
IF protocol for VIP antibody 16233-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Immun Inflamm Dis

Vasoactive intestinal peptide exerts therapeutic action by regulating PTEN in a model of Sjögren's disease

Authors - Yixi Li

Pharm Biol

Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4 + type 9 helper T cells and the VIP-VPAC2 signalling pathway

Authors - Muhua Huang

Cell Rep

PMID: 31509750

Authors - Jing Xue